Abstract
Recently, the addition of drugs with prominent 5-HT2 receptor antagonist properties (risperidone, olanzapine, mirtazapine, and mianserin) to selective serotonin reuptake inhibitors (SSRIs) has been shown to enhance therapeutic responses in patients with major depression and treatment-refractory obsessive–compulsive disorder (OCD). These 5-HT2 antagonists may also be effective in ameliorating some symptoms associated with autism and other pervasive developmental disorders (PDDs). At the doses used, these drugs would be expected to saturate 5-HT2A receptors. These findings suggest that the simultaneous blockade of 5-HT2A receptors and activation of an unknown constellation of other 5-HT receptors indirectly as a result of 5-HT uptake inhibition might have greater therapeutic efficacy than either action alone. Animal studies have suggested that activation of 5-HT1A and 5-HT2C receptors may counteract the effects of activating 5-HT2A receptors. Additional 5-HT receptors, such as the 5-HT1B/1D/5/7 receptors, may similarly counteract the effects of 5-HT2A receptor activation. These clinical and preclinical observations suggest that the combination of highly selective 5-HT2A antagonists and SSRIs, as well as strategies to combine high-potency 5-HT2A receptor and 5-HT transporter blockade in a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589–599.
Aghajanian GK, Marek GJ (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825: 161–171.
Ansoms C, De Backer-Dierick G, Vereecken JLTM (1977). Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon). Acta Psychiatr Scand 55: 116–122.
Araneda R, Andrade R (1991). 5-Hydroxytryptamine2 and 5-Hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40: 399–412.
Arango V, Underwood MD, Gubbi AV, Mann JJ (1995). Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 688: 121–133.
Arnt J, Hyttel J (1989). Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161: 45–51.
Ashby CR, Edwards E, Wang RY (1994). Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17: 173–181.
Bengtsson HJ, Kele J, Johansson J, Hjorth S (2000). Interaction of the antidepressant mirtazapine with α2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn-Schmiedebergs Arch Pharmacol 362: 406–412.
Berendse HW, Groenewegen HJ (1990). Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. J Comp Neurol 299: 187–228.
Berendse HW, Groenewegen HJ (1991). Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42: 73–102.
Berendsen HHG, Broekkamp CLE (1991). Attentuation of 5-HT-1A and 5-HT-2 but not 5-HT-1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology 105: 219–224.
Berendsen HHG, Jenck F, Broekkamp CLE (1990). Involvement of 5-HT1C receptors in drug induced penile erections in rats. Psychopharmacology 101: 57–61.
Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N (1990). 5-HT2 receptor antagonism in dysthymic disorder: a double blind placebo-controlled study with ritanserin. Acta Physiol Scand 83: 244–248.
Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA (2000). Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuro Report 11: 2017–2020.
Bogetto F, Bellino S, Vaschetto P, Ziero S (2000). Olanzapine augmentation of fluvoxamine-refractory obsessive–compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96: 91–98.
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioceptor binding profile of the atypical antipsychotic olazepine. Neuro psychopharmacology 14: 87–96.
Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L et al (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases extracellular norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160: 353–361.
Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH (1999). Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60: 45–49.
Carpenter LL, Yasmin S, Price LH (2002). A double-blind placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51: 183–188.
Cryan JF, Lucki I (2000). Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 295: 1120–1126.
Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P (1998). Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 31: 48–54.
Davis R, Whittington R, Bryson HM (1997). Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53: 608–636.
Dawson LA, Nguyen HP, Li P (2000). In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 130: 23–26.
Dawson LA, Nguyen HQ, Li P (2001). The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25: 662–668.
De Boer T (1996). The pharmacologic profile of mirtazepine. J Clin Psychiatry 57: 19–25.
De Boer T, Nefkens F, Van Helvoirt A, Van Delft AML (1996). Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 277: 852–860.
De Haan L, Linszen DH, Gorsira R (1999). Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disturbances. J Clin Psychiatry 60: 364–365.
De Haan L, Bevk N, Hoogenboom B, Dingemans P, Linzen D (2002). Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent onset schizophrenia as related disorders. J Clin Psychiatry 63: 104–107.
DeBerdt R (1976). Pipamperone (Dipiperon) in the treatment of behavioural disorders: a large scale multicentre evaluation. Acta Psychiatr Belg 76: 157–166.
Delgado PL, Chamey DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990). Serotonergie function and the mechanism of antidepressant action. Reversal of antidepressant induced remission by rapid depletion of plasma typtophan. Arch Gen Psychiatry 47: 411–418.
Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Morens FA et al (1999). Tryptophan-depletion challange in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46: 212–220.
Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597–606.
Edwards JG, Anderson I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507–533.
Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD (1990). Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311–315.
Fawcett J, Barkin RL (1998). Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51: 267–285.
Ferreri M, Lavergne F, Berlin I, Payan C, Peuch AJ (2001). Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103: 66–72.
Francken JB, Jurzak M, Vanhauwe JFM, Luyten WHML, Leysen JE (1998). The human 5-HT5A/5B receptor couples to Gi/Gi proteins and inhibits adenylate cyclase in HEK 293 cells. Eur J Pharmacol 361: 299–309.
Fuster JM (1997). The Prefrontal Cortex: Anatomy, Physiology, and Neuropsychology of the Frontal Lobe, 3rd edn. Lippincott-Raven: Philadelphia, New York.
Granhoff MI, Lee L, Jackson A, Patel K, Martinez Y, Ashby CR et al (1992). The interaction of 5-HT1A and 5-HT2 receptors in the medial prefrontal cortex: behavioral studies. Soc Neurosci Abstr 18: 1380.
Grossman F, Potter WZ, Brown EA, Maislin G (1999). A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 56: 237–243.
Haddjeri N, Blier P, de Montigny C (1997). Effects of long-term treatment with the α2-adrenoceptor antagonist mirtazepine on 5-HT neurotransmission. Naunyn-Schmiedebergs Arch Pharmacol 355: 20–29.
Haegeman J, Duyck E (1978). A retrospective evaluation of pipamperone (Dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatr Belg 78: 393–398.
Healy DJ, Meador-Woodruff JH (1999). Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain. Neuropsychopharmacology 21: 341–351.
Hoyer D, Schoeffter P, Waeber C, Palacios JM (1990). Serotonin 5-HT1D receptors. Ann NY Acad Sci 600: 168–181.
Jacobsen FM (1995). Risperidone in the treatment of affective illness and obsessive–compulsive disorder. J Clin Psychiatry 56: 423–429.
Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA (1990). Gepirone in the treatment of major depression. J Clin Psychopharmacol 10: 77S–85S.
Jolly DC, Richards JB, Seiden LS (1999). Serotonergic mediation of DRL 72s behavior: receptor subtype involvement in a behavioral screen for antidepressant drugs. Biol Psychiatry 45: 1151–1162.
Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286–293.
Kehne JH, Baron BM, Carr AA, Chaney SR, Elands J, Feldman DJ et al (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a!potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968–981.
Kern U, Richter (1985). Clinical comparison of etoperidone and amitriptyline in endogenous depressive patients. Pharmacopsychiatry 18: 94–95.
Khullar A, Chue P, Tibbo P (2001). Quetiapine and obsessive–compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 26: 55–59.
Kinney GG, Taber MT, Gribkoff VK (2000). The augmentation hypothesis for improvement of antidepressant therapy. Mol Neurobiol 21: 137–152.
Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). Mirtazapine treatment of obsessive–compulsive disorder. J Clin Psychopharmacol 21: 537–538.
Lapierre YD, Silverstone P, Reesal RT, Saxena B, Turner P, Bakish D et al (1998). A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. J Clin Psychopharmacol 18: 268–273.
Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S et al (2001). Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 6: 579–585.
Licht RW, Qvitzau S (2002). Treatment strategies in patients with major depression not responding to first-line sertraline treatment. Psychopharmacology 161: 143–151.
Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A (2000). Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol 10: 385–387.
Maes M, Libbrecht I, Van Hunsel F, Campens D, Meltzer HY (1999). Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177–182.
Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001). Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40: 887–894.
Marek GJ, Li AA, Seiden LS (1989a). Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of-low-rate 72-second schedule. J Pharmacol Exp Ther 250: 52–59.
Marek GJ, Li AA, Seiden LS (1989b). Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. J Pharmacol Exp Ther 250: 60–71.
Marek GJ, Martin-Ruiz R, Abo A, Artigas F (2001a). Synergistic ‘antidepressant-like’ action between a highly selective 5-HT-2A antagonist (M100907) and the SSRI fluoxetine on DRL 72-s behavior. Soc Neurosci Abstr 27: 975.8.
Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001b). A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in neocortex. Neuroscience 105: 113–126.
Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 109: 2–11.
Marek GJ, Seiden LS (1988). Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential-reinforcement-of-low-rate 72-second schedule. J Pharmacol Exp Ther 244: 650–658.
Marek GJ, Seiden LS (1994). Antidepressant drug screens and the serotonin system. In: Palomo T, Archer T (eds). Strategies for Studying Brain Disorders: Depressive, Anxiety and Drug Abuse Disorders. Farrand Press: London. Vol 1, pp 23–40.
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913–924.
Martin P, Waters N, Carlsson A, Carlsson ML (1997). The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104: 561–564.
Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat J-L, Muscatelli F et al (1993). Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol 43: 313–319.
Matussek VN, Benkert O, Fidetzis K, Flach D, Hermann HU, Kaumeier S et al (1976). Wirkung des Anthracenderivats danitracen (WA 335-BS) im vergleich zu amitriptylin bie depressiven patienten. Arzneim Forsch (Drug Res) 26: 1160.
McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A et al (1995a). Lack of efficacy of clozapine monotherapy in refractory obsessive–compulsive disorder. Am J Psychiatry 152: 1812–1814.
McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH (1995b). Risperidone addition in fluvoxamine-refractory obsessive–compulsive disorder: three cases. J Clin Psychiatry 56: 526–528.
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibition-refractory obsessive–compulsive disorder. Arch Gen Psychiatry 57: 794–801.
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition to fluvoxamine-refractory obsessive–compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51: 302–308.
McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders [see comments]. Arch Gen Psychiatry 55: 633–641.
McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH (1996). Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 53: 993–1000.
Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tanredi A et al (2000). Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citaloporam. Eur J Neurosci 12: 1079–1095.
Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA et al (2001). RNA editing of the human serotonin 5-HT2C receptor: alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 24: 478–491.
Noordhuizen GJM (1977). Treating severe maladjustment with pipamperone (Dipiperon). Acta Psychiatr Belg 77: 754–760.
Nordstrom A-L, Farde L, Halldin C (1993). High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110: 365–367.
Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999). Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenia patients. Am J Psychiatry 156: 869–875.
O'Connor M, Silver H (1998). Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 18: 89–90.
Osman OT, Rudorfer MV, Potter WZ (1989). Idazoxan: a selective α2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 46: 958–959.
Ostroff RB, Nelson JC (1999). Risperidone augmentation of SSRIs in major depression. J Clin Psychiatry 60: 256–259.
Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F (1999). A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 56: 375–379.
Pinder RM, Fink M (1982). Mianserin. Mod Probl Pharmacopsychiatry 18: 70–101.
Pineyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. The American Society for Pharmacology and Therapeutics. Vol. 51: 533–591.
Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDouble CJ (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 11: 267–277.
Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19: 37–44.
Potter WZ, Grossman F, Dawkins K, Manji HK (1994). Initial clinical psychopharmacological studies of alpha-2 adrenoceptor antagonists in volunteers and depressed patients. In: Montgomery SA, Corn TH (eds). Psychopharmacology of Depression, Vol British Association for Psychopharmacology Monograph No. 13. Oxford University Press: New York.
Poyurovsky M, Dorfman-Etrog P, Hermesh H, Munitz H, Tollefson GD, Weizman A (2000). Beneficial effect of olanzapine in schizophrenic patients with obsessive–compulsive symptoms. Int Clin Psychopharmacol 15: 169–173.
Puller IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S (2000). LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine2A receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol 407: 39–46.
Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996). Therapeutic effect and safety of adjunctive risperidone in refractory obsessive–compulsive disorder (OCD). Psychopharmacol Bull 32: 677–682.
Research Units on Pediatric Psychopharmacology Autism Network (2002). A double-blind placebo-controlled trial of risperidone in children with autistic disorder. N Engl J Medicine (in press).
Richelson E (2001). Pharmacology of antidepressants. Mayo Clin Proceed 76: 511–527.
Richelson E, Nelson A (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94–102.
Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29–39.
Robinson DS, Rickels K, Feighner J, Fabre LF, Gammans RE, Shrotriya RC et al (1990). Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10: 67S–76S.
Rollema H, Clarke T, Sprouse JS, Schulz DW (1996). Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem 67: 437–439.
Saxena S, Wang D, Bystritsky A, Baxter Jr LR (1996). Risperidone augmentation of SRI treatments for refractory obsessive–compulsive disorder. J Clin Psychiatry 57: 303–306.
Schmidt CJ, Fox CB, Harms JF, Wylie P, Seeger TF, Guanowsky V et al (2001). CP-646,781: a potent dual SSRI/5-HT2A receptor agonist. Soc Neurosci Abstr 27: 665.17.
Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57–73.
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). (1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine(5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273: 101–112.
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG et al (2001). A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131–134.
Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH (1999). Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21: 622–631.
Standal JE (1977). Pizotifen as an antidepressant Acta Physiol Scand 56: 276–279.
Stein DJ, Bouwer MB, Hawkridge S, Emsley RA (1997). Risperidone augmentation of serotonin reuptake inhibitors in obsessive–compulsive and related disorders. J Clin Psychiatry 58: 119–122.
Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Fredman L, Raj Kowska G et al (1998). Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression—postmortem evidence for decreased serotonin activity. J Neurosci 18: 7394–7401.
Stoll AL, Haura G (2000). Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 20: 495–496.
Su HS, Bentivoglio M (1990). Thalamic midline cell populations projecting to the nucleus accumbens, amygdala, and hippocampus in the rat. J Comp Neurol 297: 582–593.
Talvik-Lofti M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F et al (2000). High 5-HT2A receptor occupancy in M100907-treated schizophrenia patients. Psychopharmacology 148: 400–403.
Tanaka E, North RA (1993). Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 69: 1749–1757.
Tandon R, Harrigan E, Zorn SH (1997). Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4: 159–177.
van Hemert JCJ (1975). Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo-controlled cross-over study with long-term follow-up. Acta Physiol Scand 52: 237–245.
Van Renynghe de Voxvrie G, De Bie M (1976). Character neuroses and behavioural disorders in children: their treatment with pipamperone (Dipiperon): a clinical study. Acta Psychiatr Belg 76: 688–694.
Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ et al (2001). Modulation of 5-HT2A receptor-mediated head-twitch behavior in the rat by 5-HT2C receptor agonists. Pharmacol Biochem Behav 69: 643–652.
Wander TJ, Nelson A, Okazaki H, Richelson E (1986). Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol 132: 115–121.
Weiss EL, Potenza MN, McDougle CJ, Epperson CN (1999). Olanzapine addition to obsessive–compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60: 524–527.
Willins DL, Meltzer HY (1997). Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282: 699–706.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marek, G., Carpenter, L., McDougle, C. et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacol 28, 402–412 (2003). https://doi.org/10.1038/sj.npp.1300057
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300057
Keywords
This article is cited by
-
Progesterone receptor distribution in the human hypothalamus and its association with suicide
Acta Neuropathologica Communications (2024)
-
D1R-5-HT2AR Uncoupling Reduces Depressive Behaviours via HDAC Signalling
Neurotherapeutics (2023)
-
A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine
Translational Psychiatry (2022)
-
Association between autism spectrum disorder and polymorphisms in genes encoding serotine and dopamine receptors
Metabolic Brain Disease (2021)
-
Expression of serotonin 1A and 2A receptors in molecular- and projection-defined neurons of the mouse insular cortex
Molecular Brain (2020)
